US FDA approves smart diabetes monitoring system
The US Food and Drug Administration has given the go-ahead to the integration of LifeScan’s blood glucose monitoring systems and WellDoc’s digital diabetes management platform. LifeScan provides blood glucose data via LifeScan's One Touch, while WellDoc's mobile diabetes management platform, BlueStar offers real-time user feedback, based on patterns of behaviour, as well as virtual coaching. LifeScan, a subsidiary of Johnson & Johnson, and WellDoc's collaboration aims to offer a "connected patient experience".

The FDA has cleared the wireless integration of one of Johnson and Johnson subsidiary LifeScan’s blood glucose monitoring systems and WellDoc’s digital diabetes management platform for people with type 2 diabetes.

The two companies originally teamed up in March of this year. The integrated system consists of OneTouch Verio Flex, LifeScan’s Bluetooth smart blood glucose monitoring system and companion app, and WellDoc’s FDA-cleared mobile diabetes management platform, BlueStar.

Using blood glucose data from OneTouch, BlueStar’s platform identifies trends and patterns, sending information to the user’s healthcare team while offering the user individualized feedback in real time. It also offers virtual coaching based on their specific care plan, and the whole system works with the OneTouch Reveal mobile app.

The two companies are currently working with health plans to expand access to the integrated system.

"Our partnership with WellDoc highlights our sustained commitment in helping to drive better health outcomes by building a more connected patient experience,” LifeScan’s World Wide President Valerie Asbury said in a statement. “Integrating digital solutions such as OneTouch Reveal mobile app and BlueStar will help patients self-manage their diabetes and create value for health care providers.”